US Government Backs Hikma's Supreme Court Appeal in Vascepa Generic Patent Dispute
Key Insights
The US Solicitor General urged the Supreme Court to hear Hikma Pharmaceuticals' appeal challenging a ruling that found the company induced patent infringement through its generic Vascepa labeling.
The government argued that Hikma shouldn't be penalized for using a "skinny label" that accurately described their product as the generic version of Amarin's heart medication.
The case centers on Vascepa, a heart medicine approved in 2012 for treating excessive triglycerides (search) and expanded in 2019 for additional cardiovascular indications.
The US federal government has thrown its support behind Hikma Pharmaceuticals USA Inc. in a high-stakes patent dispute that could reshape how generic drug companies label their products. US Solicitor General D. John Sauer filed an amicus brief urging the Supreme Court to hear Hikma's appeal of an appeals court ruling that found the company induced patent infringement through its generic version of Amarin Pharma Inc.'s heart medication Vascepa.
Government Defends "Skinny Label" Practice
The Solicitor General argued that Hikma shouldn't face punishment for employing a so-called "skinny label" that "accurately described their drug as the generic version" of Vascepa. This labeling approach represents a common practice in the generic pharmaceutical industry, where companies seek to avoid patent infringement by limiting their product labels to cover only non-patented uses of a drug.
The appeals court had previously ruled that Hikma induced doctors or pharmacists to prescribe its generic heart medicine for off-label, patent-infringing uses, creating potential liability for the generic manufacturer despite its careful labeling approach.
Vascepa's Clinical Applications
At the center of this legal battle is Vascepa, Amarin's heart medicine that received FDA approval in 2012 for treatment of excessive levels of triglycerides in the blood. The drug's approved indications expanded significantly in 2019 when it received additional approval for treatment of cardiovascular conditions (search), broadening its therapeutic scope and commercial potential.
Implications for Generic Drug Industry
The Supreme Court's decision on whether to hear this case could have far-reaching consequences for the generic pharmaceutical industry. The dispute touches on fundamental questions about how generic manufacturers can protect themselves from patent infringement claims while still providing physicians and patients with necessary information about their products.
The case represents a critical test of the balance between patent protection for innovative pharmaceutical companies and the ability of generic manufacturers to bring lower-cost alternatives to market through careful labeling practices.